| Bioactivity | PAD-IN-2 is a potent pad4 inhibitor (IC50: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis[1]. | ||||||||||||
| Invitro | PAD-IN-2 (Example-57, 1 h) inhibits PAD4 activity with an IC50 value <1 μM (determined by ammonia release biochemical assay)[1]. | ||||||||||||
| Name | PAD-IN-2 | ||||||||||||
| CAS | 2304852-21-7 | ||||||||||||
| Formula | C27H28ClN5O2 | ||||||||||||
| Molar Mass | 490.00 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hallur, Gurulingappa, et al. Heterocyclic compounds as pad4 inhibitors. Patent WO2019058393 A1. |